HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

655

Participants

Timeline

Start Date

November 26, 2019

Primary Completion Date

May 8, 2024

Study Completion Date

December 1, 2026

Conditions
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions
DRUG

Vutrisiran

Vutrisiran will be administered by SC injection.

DRUG

Sterile Normal Saline (0.9% NaCl)

Sterile normal saline (0.9% NaCl) will be administered by SC injection.

Trial Locations (79)

10032

Clinical Trial Site, New York

11030

Clinical Trial Site, Manhasset

19104

Clinical Trial Site, Philadelphia

20010

Clinical Trial Site, Washington D.C.

27710

Clinical Trial Site, Durham

30501

Clinical Trial Site, Gainesville

44195

Clinical Trial Site, Cleveland

55902

Clinical Trial Site, Rochester

60201

Clinical Trial Site, Evanston

77030

Clinical Trial Site, Houston

94305

Clinical Trial Site, Stanford

02115

Clinical Trial Site, Boston

02118

Clinical Trial Site, Boston

Unknown

Clinical Trial Site, Buenos Aires

Clinical Trial Site, Adelaide

Clinical Trial Site, Melbourne

Clinical Trial Site, Sydney

Clinical Trial Site, Westmead

Clinical Trial Site, Woolloongabba

Clinical Trial Site, Vienna

Clinical Trial Site, Anderlecht

Clinical Trial Site, Dendermonde

Clinical Trial Site, Ghent

Clinical Trial Site, Leuven

Clinical Trial Site, Québec

Clinical Trial Site, Toronto

Clinical Trial Site, Zagreb

Clinical Trial Site, Olomouc

Clinical Trial Site, Prague

Clinical Trial Site, Aarhus

Clinical Trial Site, Odense

Clinical Trial Site, Créteil

Clinical Trial Site, Marseille

Clinical Trial Site, Paris

Clinical Trial Site, Toulouse

Clinical Trial Site, Essen

Clinical Trial Site, Göttingen

Clinical Trial Site, Heidelberg

Clinical Trial Site, Leipzig

Clinical Trial Site, Münster

Clinical Trial Site, Würzburg

Clinical Trial Site, Budapest

Clinical Trial Site, Dublin

Clinical Trial Site, Haifa

Clinical Trial Site, Aichi

Clinical Trial Site, Fukuoka

Clinical Trial Site, Kagawa

Clinical Trial Site, Kashihara

Clinical Trial Site, Kumamoto

Clinical Trial Site, Matsumoto

Clinical Trial Site, Nankoku

Clinical Trial Site, Osaka

Clinical Trial Site, Tokyo

Clinical Trial Site, Riga

Clinical Trial Site, Kaunas

Clinical Trial Site, Groningen

Clinical Trial Site, Utrecht

Clinical Trial Site, Oslo

Clinical Trial Site, Lima

Clinical Trial Site, San Miguel

Clinical Trial Site, Gdansk

Clinical Trial Site, Wroclaw

Clinical Trial Site, Guimarães

Clinical Trial Site, Lisbon

Clinical Trial Site, Porto

Clinical Trial Site, Seoul

Clinical Trial Site, Barcelona

Clinical Trial Site, Bilbao

Clinical Trial Site, Huelva

Clinical Trial Site, Madrid

Clinical Trial Site, Málaga

Clinical Trial Site, Gothenburg

Clinical Trial Site, Umeå

Clinical Trial Site, Birmingham

Clinical Trial Site, Cardiff

Clinical Trial Site, Glasgow

Clinical Trial Site, London

Clinical Trial Site, Manchester

Clinical Trial Site, Middlesbrough

Sponsors
All Listed Sponsors
lead

Alnylam Pharmaceuticals

INDUSTRY